Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | $11.00 → $9.00 | Hold → Sell | Deutsche Bank |
| 2/26/2024 | $23.00 | Market Perform | Leerink Partners |
| 2/20/2024 | Hold → Reduce | HSBC Securities | |
| 1/3/2024 | $21.00 | Underweight | Barclays |
| 12/22/2023 | $27.00 | Hold | HSBC Securities |
| 10/23/2023 | $27.00 → $30.00 | Neutral → Overweight | JP Morgan |
| 7/3/2023 | $37.00 → $27.00 | Underweight | Morgan Stanley |
| 6/28/2023 | $46.00 → $34.00 | Buy → Hold | Deutsche Bank |
For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal
Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously
Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
More than 415 local health departments and community organizations mobilize across the country for largest-ever National HIV Testing Day event Walgreens and Greater Than HIV/STDs, a public information campaign from KFF, are joining with health departments and community organizations to provide free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for the nation's largest National HIV Testing Day (NHTD) event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612760766/en/ With more than 415 local testing partners in nearly all states, Washington, D.C. and Puerto Rico, this year's activat
WAG advertisers can now accelerate audience creation, activation, and measurement with flexibility and speed LiveRamp (NYSE:RAMP), the leading data collaboration partner, today announced it is powering Walgreens Advertising Group's (WAG) clean room solution. The partnership enables WAG, the retail media division of Walgreens, to increase access to its first-party data at speed, scale audience insights, and offer more transparency and control to advertisers. This enables brands to enhance media measurement across all platforms in the digital ecosystem and improve ROI with faster time-to-value. LiveRamp's data collaboration network enables WAG to unlock new insights, accelerate performanc
The facility will support nearly 200 stores regionally with the dispensing and shipping of prescriptions, allowing pharmacists to spend more time with patients. Walgreens is continuing to invest in innovative pharmacy solutions with the opening of a new micro-fulfillment center (MFC) in Brooklyn Park, Minnesota. This facility will streamline prescription processing and reduce administrative tasks, freeing up pharmacists to focus more on delivering personalized care to their patients. This new facility will support nearly 200 Walgreens stores across the Midwest, including 145 in Minnesota alone, and is expected to process approximately 13 million prescriptions each year. It will also bring
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior
Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors is suspending the company's cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company's broader long-term turnaround efforts. This change in capital allocation is aimed at strengthening WBA's balance sheet by reducing debt over time and improving free cash flow, as the company works toward achieving a retail pharmacy-led turnaround underpinned by a sustainable economic model. The company's cash needs over the next several years, including with respect to litigation and debt refinancing,